Figures & data
Table I. Patient demographics by light transmission aggregometry.
Table II. Patient demographics by thrombelastography platelet mapping assay.
Table III. Age-specific prevalence of aspirin resistance or semiresponders in patients with cardiovascular disease.
Table IV. Occurrence of composite end point in the aspirin-resistant patients or semiresponders and aspirin-sensitive patients.
Figure 1. Kaplan–Meier curves of probability of freedom from composite end point according to response to aspirin therapy. Composite end point included myocardial infarction, stroke, transient ischemic attack and unstable angina. Patients were defined as aspirin resistant by different methods.
Table V. Hazard ratios of the composite end point by Cox proportional hazards regression.
